A PHASE 1B, TWO-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORAL PF-07054894 IN ADULT PARTICIPANTS AGED 18-75 YEARS WITH MILD TO SEVERE ULCERATIVE COLITIS
Latest Information Update: 28 Jan 2025
At a glance
- Drugs PF-07054894 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Oct 2024 Planned number of patients changed from 47 to 27.
- 08 Oct 2024 Status changed from active, no longer recruiting to recruiting.
- 30 Jul 2024 Planned number of patients changed from 27 to 47.